Melt crystallization and thermal degradation profile of the antichagasic drug nifurtimox
; Sa-Barreto, Livia ; Gratieri, Tais ; Gelfuso, Guilherme M. ; Salomon, Claudio Javier
; Cunha Filho, Marcílio Otros responsables
Fecha
02/2024
Editorial
Elsevier Science
Revista
Journal of Pharmaceutical and Biomedical Analysis
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
0731-7085
eISSN
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
Despite nifurtimox (NFX) being a traditional drug for treating Chagas disease, some of its physicochemical properties are still unknown, especially its thermal behavior, which brings important outcomes regarding stability and compatibility. In this work, a comprehensive study of NFX´s thermal properties was conducted to assist incremental innovations that can improve the efficacy of this drug in novel pharmaceutical products. For this purpose, thermal analyses associated with spectroscopy and spectrometry techniques were used. DSC analyses revealed that the melt crystallization of the NFX led to its amorphous form with the possible formation of a minor fraction of a different crystalline phase. Coats-Redfern method using TGA results indicated the activation energy of NFX non-isothermal degradation as 348.8 ± 8.2 kJ mol−1, which coincides with the C-NO2 bond dissociation energy of the 2-nitrofuran. Investigation of the isothermal degradation kinetics using FTIR 2D COS showed the possible detachment of radical NO2 and ethylene from the NFX structure, which could affect its mechanism of action. A preliminary mechanism for the thermal degradation of this drug was also proposed. The results enhanced the understanding of NFX´s thermal properties, providing valuable insights, especially for developing NFX-based pharmaceutical products that involve thermal processing.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
